文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]AlF-NOTA-FAPI-04 PET/CT可预测不可手术胰腺导管腺癌化疗患者的治疗反应与生存

[18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-06-17

该前瞻性研究纳入47例病理确诊的原发性胰腺导管腺癌(PDAC)患者,于化疗前及一周期化疗后行[18F]AlF-NOTA-FAPI-04 PET/CT,并分析基线PET变量与癌相关成纤维细胞(CAF)标志物的相关性。结果显示基线MTV与不可手术PDAC患者生存相关(MTV HR=1.016,P=0.016),ΔMTV预测治疗反应优于ΔCA19-9。

要点

  • 基线MTV较高与不可手术PDAC患者生存较差相关(HR=1.016,P=0.016)。
  • 化疗前后SUVmax、MTV和TLF变化较大与治疗反应良好相关(均P<0.05)。
  • ΔMTV、ΔTLF、ΔSUVmax预测治疗反应的曲线下面积大于ΔCA19-9。

核心结论

  • 基线[18F]AlF-NOTA-FAPI-04 PET/CT的MTV较高与不可手术PDAC患者生存较差相关。
  • ΔMTV预测治疗反应比ΔCA19-9更敏感,有助于识别疾病进展高风险的PDAC患者。

研究设计与样本

  • 前瞻性纳入47例组织病理学确诊的原发性PDAC患者,化疗前行[18F]AlF-NOTA-FAPI-04 PET/CT检测肿瘤表面成纤维细胞激活蛋白(FAP)。
  • 对PDAC标本进行癌相关成纤维细胞(CAF)标志物免疫组化染色,并在一个周期化疗后行第二次PET扫描以研究FAPI摄取变量的变化。

主要发现

  • FAPI PET变量SUVmax、SUVmean、MTV和TLF与CAF标志物(FAP、α平滑肌肌动蛋白、波形蛋白、S100A4和血小板衍生生长因子受体α/β)呈正相关(均P<0.05)。
  • MTV与不可手术PDAC患者生存相关(均P<0.05);Cox多因素回归显示MTV与总生存相关(MTV HR=1.016,P=0.016)。
  • 化疗前后SUVmax、MTV和TLF变化较大与治疗反应良好相关(均P<0.05)。
  • ΔMTV、ΔTLF和ΔSUVmax预测治疗反应的曲线下面积大于ΔCA19-9。
  • Kaplan-Meier分析显示MTV和TLF治疗前后变化程度可预测无进展生存,基于中位数的截断值分别为ΔMTV -4.95(HR=8.09,P=0.013)和ΔTLF -77.83(HR=4.62,P=0.012)。

关键数值与推荐

  • 采用RECIST v.1.1标准区分治疗反应良好与不良,并用受试者工作特征(ROC)曲线分析确定最佳截断值。
  • ΔMTV截断值为-4.95(基于中位数),预测无进展生存的HR=8.09,P=0.013。
  • ΔTLF截断值为-77.83(基于中位数),预测无进展生存的HR=4.62,P=0.012。
  • Cox多因素回归显示MTV与总生存相关,HR=1.016,P=0.016。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated whether uptake of [18F] AlF-NOTA-FAPI-04 on positron emission tomography/computed tomography (PET/CT) could predict treatment response and survival in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: We prospectively evaluated 47 patients with histopathologically confirmed primary PDAC who provided pretreatment [18F] AlF-NOTA-FAPI-04 scans to detect fibroblast activation protein (FAP) on the tumor surface by uptake of [18F] AlF-NOTA-FAPI-04. PDAC specimens were immunohistochemically stained with cancer-associated fibroblast (CAF) markers. We obtained a second PET scan after one cycle of chemotherapy to study changes in FAPI uptake variables from before to during treatment. Correlations between baseline PET variables and CAF-related immunohistochemical markers were assessed with Spearman's rank test. Cox regression and Kaplan-Meier methods were used to assess relationships between disease progression and potential predictors. Receiver operating characteristic (ROC) curve analysis was used to define the optimal cut-off points for distinguishing patients according to good response vs. poor response per RECIST v.1.1. RESULTS: The FAPI PET variables maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion FAP expression (TLF) were positively correlated with CAF markers (FAP, α-smooth muscle actin, vimentin, S100A4, and platelet-derived growth factor receptor α/β, all P < 0.05). MTV was associated with survival in patients with inoperable PDAC (all P < 0.05). Cox multivariate regression showed that MTV was associated with overall survival (MTV hazard ratio [HR] = 1.016, P = 0.016). Greater changes from before to during chemotherapy in SUVmax, MTV, and TLF were associated with good treatment response (all P < 0.05). ΔMTV, ΔTLF, and ΔSUVmax had larger areas under the curve than ΔCA19-9 for predicting treatment response. Kaplan-Meier analysis showed that the extent of change in MTV and TLF from before to after treatment predicted progression-free survival, with cut-off values (based on medians) of - 4.95 for ΔMTV (HR = 8.09, P = 0.013) and - 77.83 for ΔTLF (HR = 4.62, P = 0.012). CONCLUSIONS: A higher baseline MTV on [18F] AlF-NOTA-FAPI-04 scans was associated with poorer survival in patients with inoperable PDAC. ΔMTV was more sensitive for predicting response than ΔCA19-9. These results are clinically meaningful for identifying patients with PDAC who are at high risk of disease progression.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhu Z, Cheng K, Yun Z, et al. [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37328622. doi:10.1007/s00259-023-06271-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。